Amneal Pharmaceuticals (NYSE:AMRX) had its price target reduced by research analysts at SunTrust Banks from $16.00 to $9.00 in a research note issued to investors on Thursday, The Fly reports. The firm currently has a “buy” rating on the stock. SunTrust Banks’ price target would suggest a potential upside of 143.24% from the stock’s current price. SunTrust Banks also issued estimates for Amneal Pharmaceuticals’ Q2 2019 earnings at $0.14 EPS.

Other analysts have also issued research reports about the company. Barclays restated a “hold” rating on shares of Bank of Montreal in a report on Tuesday, June 11th. Piper Jaffray Companies set a $92.00 price objective on Wintrust Financial and gave the company a “buy” rating in a report on Monday, July 8th. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. BMO Capital Markets upped their price objective on Sun Life Financial from C$58.00 to C$60.00 in a report on Friday, May 10th. Finally, Raymond James upped their price objective on S&P Global from $226.00 to $246.00 and gave the company an “outperform” rating in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $14.58.

Shares of Amneal Pharmaceuticals stock opened at $3.70 on Thursday. The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.37 and a current ratio of 2.11. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 4.35, a price-to-earnings-growth ratio of 0.25 and a beta of 1.50. The company has a fifty day moving average price of $7.12. Amneal Pharmaceuticals has a fifty-two week low of $3.69 and a fifty-two week high of $24.48.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.07). The firm had revenue of $446.00 million during the quarter, compared to analyst estimates of $438.18 million. Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. As a group, equities research analysts expect that Amneal Pharmaceuticals will post 0.91 EPS for the current year.

In related news, SVP Joseph Todisco bought 15,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were bought at an average cost of $9.88 per share, with a total value of $148,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Pradeep Bhadauria bought 7,000 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were bought at an average cost of $8.48 per share, for a total transaction of $59,360.00. The disclosure for this purchase can be found here. Insiders have bought 41,000 shares of company stock worth $387,300 over the last ninety days. 26.34% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the stock. Quantamental Technologies LLC raised its position in Amneal Pharmaceuticals by 34.0% during the first quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after buying an additional 1,700 shares during the period. Legal & General Group Plc raised its position in Amneal Pharmaceuticals by 5.5% during the fourth quarter. Legal & General Group Plc now owns 34,505 shares of the company’s stock valued at $467,000 after buying an additional 1,810 shares during the period. Oppenheimer Asset Management Inc. raised its position in Amneal Pharmaceuticals by 11.1% during the first quarter. Oppenheimer Asset Management Inc. now owns 18,269 shares of the company’s stock valued at $259,000 after buying an additional 1,828 shares during the period. Brinker Capital Inc. raised its position in Amneal Pharmaceuticals by 11.1% during the first quarter. Brinker Capital Inc. now owns 21,110 shares of the company’s stock valued at $299,000 after buying an additional 2,105 shares during the period. Finally, Bessemer Group Inc. acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at $34,000. 36.05% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Story: CBOE Russell 2000® Volatility Index

The Fly

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.